CVE:ADKDiagnos Stock Price, Forecast & News

C$0.17

-0.01 (-5.56 %)

(As of 06/3/2020 12:59 PM ET)

Add

Compare

Today's Range

C$0.17

Now: C$0.17▼

C$0.18

50-Day Range

C$0.16

MA: C$0.18▼

C$0.22

52-Week Range

C$0.10

Now: C$0.17▼

C$0.38

Volume16,033 shs

Average Volume52,070 shs

Market CapitalizationC$10.43 million

P/E RatioN/A

Dividend YieldN/A

BetaN/A

DIAGNOS Inc. provides software-based interpretation services primarily in Canada, the United Arab Emirates, Saudi Arabia, Slovakia, and the United States. It offers image analysis services through Computer Assisted Retinal Analysis, a software tool that assists health specialists in the detection of diabetic retinopathy. DIAGNOS Inc. has a collaboration agreement with ÉTS, École de technologie supérieure. The company was founded in 1998 and is headquartered in Brossard, Canada.

Beat the Market (BTM) Rank^™

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for Diagnos.

2.3 Community Rank

Outperform Votes
Diagnos has received 33 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Diagnos has received 38 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Diagnos has received 53.52% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Diagnos and other stocks. Vote “Outperform” if you believe ADK will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ADK will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Diagnos does not currently pay a dividend.
Dividend Growth
Diagnos does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Diagnos insiders have not sold or bought any company stock.

0.0 Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Diagnos is -2.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Diagnos is -2.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Overall Beat the Market Rank^™

0.46 out of 5 stars

Industry, Sector and Symbol

Stock Exchange CVE

Industry Health Information Services

Sub-IndustryN/A

SectorComputer and Technology

Current SymbolCVE:ADK

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.diagnos.ca

Phone+1-450-6788882

Debt

Debt-to-Equity Ratio1,230.33

Current Ratio0.59

Quick Ratio0.47

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesC$344,989.00

Price / Sales30.24

Cash FlowC$0.01 per share

Price / Cash Flow25.71

Book ValueC($0.01) per share

Price / Book-18.89

Profitability

EPS (Most Recent Fiscal Year)N/A

Net IncomeN/A

Net MarginsN/A

Return on EquityN/A

Return on AssetsN/A

Miscellaneous

EmployeesN/A

Outstanding Shares61,366,000

Market CapC$10.43 million

Next Earnings Date6/3/2020 (Estimated)

OptionableNot Optionable

Receive ADK News and Ratings via Email

Sign-up to receive the latest news and ratings for ADK and its competitors with MarketBeat's FREE daily newsletter.

Diagnos (CVE:ADK) Frequently Asked Questions

How has Diagnos' stock been impacted by COVID-19 (Coronavirus)?

Diagnos' stock was trading at C$0.22 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ADK stock has decreased by 22.7% and is now trading at C$0.17. View which stocks have been most impacted by Coronavirus.

When is Diagnos' next earnings date?

Diagnos is scheduled to release its next quarterly earnings announcement on Wednesday, June 3rd 2020. View our earnings forecast for Diagnos.

Has Diagnos been receiving favorable news coverage?

News coverage about ADK stock has been trending somewhat positive on Wednesday, InfoTrie Sentiment reports. The research firm scores the sentiment of news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Diagnos earned a coverage optimism score of 1.7 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 6.0 out of 10, indicating that recent news coverage is somewhat likely to have an impact on the stock's share price in the next several days. View the latest news aboutDiagnos.

Who are some of Diagnos' key competitors?

Some companies that are related to Diagnos include Reliq Health Technologies (RHT), Novita Healthcare (NHL), Vitalhub (VHI), Induction Healthcare Group (INHC), Oneview Healthcare (ONE), 1ST Group (1ST), Emerald Clinics (EMD), ICSGlobal (ICS), Jayex Healthcare (JHL), Global Health (GLH), CardioComm Solutions (EKG), Sensyne Health (SENS), CannaOne Technologies (CNNA), CannaOne Technologies (CNONF) and Corum Group (COO). View all competitors.

What other stocks do shareholders of Diagnos own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Diagnos investors own include Aileron Therapeutics (ALRN), Axovant Gene Therapies (AXGT), Avinger (AVGR), Belmont Resources (BEA), BioNano Genomics (BNGO), CLEAR CHANNEL O/SH (CCO), Caladrius Biosciences (CLBS), CleanSpark (CLSK), Century Global Commodities (CNT) and Cocrystal Pharma (COCP).

Who are Diagnos' key executives?

Diagnos' management team includes the following people:

Mr. André Larente, CEO, Pres & Exec. Director
Mr. Marc-André Massue, VP of Fin., CFO & Sec.
Mr. Guillermo Moreno Robles, VP of Sales
Dr. Hadi Chakor Djelthia, Chief Medical Officer

What is Diagnos' stock symbol?

Diagnos trades on the Canadian Venture Exchange (CVE) under the ticker symbol "ADK."

How do I buy shares of Diagnos?

Shares of ADK and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade, and Charles Schwab.

What is Diagnos' stock price today?

One share of ADK stock can currently be purchased for approximately C$0.17.

How big of a company is Diagnos?

Diagnos has a market capitalization of C$10.43 million and generates C$344,989.00 in revenue each year.

What is Diagnos' official website?

The official website for Diagnos is www.diagnos.ca.

How can I contact Diagnos?

Diagnos' mailing address is 7005 Taschereau Blvd, Suite 340 Brossard, BROSSARD, QC J4Z 1A7, Canada. The company can be reached via phone at +1-450-6788882.

This page was last updated on 6/3/2020 by MarketBeat.com Staff

CVE:ADKDiagnos Stock Price, Forecast & News

Adding